|
業務類別
|
Biotechnology |
|
業務概覽
|
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
| 公司地址
| 1560 Trapelo Road, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 781 786-8230 |
| 傳真號碼
| +1 781 786-8866 |
| 公司網頁
| https://www.dyne-tx.com |
| 員工數量
| 258 |
| Ms. Johanna Friedl-Naderer |
Chief Commercial Officer |
美元 171.16K |
15/04/2025 |
| Mr. Erick J. Lucera, C.F.A. |
Principal Accounting Officer, Chief Financial Officer and Treasurer |
-- |
02/03/2026 |
| Dr. Oxana Beskrovnaya, PhD |
Chief Scientific Officer |
美元 506.00K |
15/04/2025 |
| Mr. John G. Cox |
Director, President and Chief Executive Officer |
美元 536.99K |
02/03/2026 |
| Mr. Douglas Kerr, M.D.,PhD |
Chief Medical Officer |
美元 172.80K |
15/04/2025 |
|
|
| Dr. Carlo Incerti, M.D. |
Independent Director |
02/03/2026 |
| Mr. Dirk Kersten |
Independent Director |
02/03/2026 |
| Mr. Vikram Karnani |
Independent Director |
02/03/2026 |
| Dr. Catherine Stehman-Breen, M.D. |
Independent Director |
02/03/2026 |
| Mr. David Charles Lubner, C.P.A.,M.S. |
Independent Director |
02/03/2026 |
| Mr. John G. Cox |
Director, President and Chief Executive Officer |
02/03/2026 |
| Mr. Edward M. Hurwitz, J.D. |
Independent Director |
02/03/2026 |
| Mr. Jason P. Rhodes |
Chairman of the Board |
02/03/2026 |
| Mr. Brian S. Posner |
Independent Director |
02/03/2026 |
|
|
|
|
